The second-line treatment with docetaxel plus PD-1/PD-L1 inhibitor in patients with stage IV NSCLC can improve the DCR and prolong the PFS, and the adverse reactions are tolerable. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.